Specific immunotherapy (hyposensitization) for IgE-mediated allergic diseases;Die spezifische immuntherapie (hyposensibilisierung) bei IgE-vermittelten allergischen erkrankungen

Allergologie

Volumn 33, Issue 1, 2010, Pages 3-34

  Kleine Tebbe, J ^a   Bufe, A ^b   Ebner, C ^c   Eigenmann, P ^d   Friedrichs, F ^e   Fuchs, T ^f   Huttegger, I ^g   Jung, K ^h   Klimek, L ⁱ   Kopp, M ^j   Lassig W ^k   Merk, H ^l   Niggemann, B ^m   Rabe, U ⁿ   Saloga, J ^o   Schmid Grendelmeier, P ^p   Sitter, H ^q   Virchow, J C ^r   Wagenmann, M ^s   Wedi, B ^t   Worm, M ^u   Hering, T ^v   Koch, A ^w   Lenders, H ^x   Musken H ^y   Schnitzer, S ^x   Stuck, B A ^z   Voigtmann, I ^aa   Wehrmann, W ^ab   Kaul, S ^ac   Luther, B ^ad   Schwalfenberg, A ^aa   more..

^a Allergie und Asthma Zentrum Westend   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Ambulatorium für Allergie und Klinische Immunologie   (Austria)

^d Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^e Praxis für Kinder und Jugendmedizin   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g Salzburger Landeskliniken   (Austria)

^h Praxis fur Dermatologie und Immunologie   (Germany)

ⁱ Zentrum fur Rhinologie und Allergologie   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

^k Krankenhaus St Elisabeth und St Barbara   (Germany)

^l UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^m DRK KLINIKEN BERLIN WESTEND   (Germany)

ⁿ Klinik III   (Germany)

^o JOHANNES GUTENBERG UNIVERSITY   (Germany)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q PHILIPPS UNIVERSITY MARBURG   (Germany)

^r UNIVERSITY OF ROSTOCK   (Germany)

^s UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^t HANNOVER MEDICAL SCHOOL   (Germany)

^u CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^v Lungenarztpraxis Tegel   (Germany)

^w UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^x Praxis für HNO Heilkunde   (Germany)

^y Praxis für Innere Medizin Allergologie und Pneumologie   (Germany)

^z UNIVERSITY OF HEIDELBERG   (Germany)

^aa Deutscher Allergie und Asthmabund eV DAAB   (Germany)

^ab Dermatologische Gemeinschaftspraxis Warendorfer Strasse   (Germany)

^ac PAUL EHRLICH INSTITUT   (Germany)

^ad Medizinischer Dienst der Krankenversicherung Hessen   (Germany)

more..

Author keywords

Allergen; Allergen extract; Allergic disease; Guideline; Hyposensitization; Specific immunotherapy; Treatment

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT;

ADAPTIVE IMMUNITY; ALLERGY; ANAPHYLAXIS; ASTHMA; DESENSITIZATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMERGENCY TREATMENT; HUMAN; IMMUNOTHERAPY; MEDICAL EDUCATION; NONHUMAN; PATIENT INFORMATION; REVIEW; RHINOCONJUNCTIVITIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

EID: 77649331096     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp33003     Document Type: Review

References (172)

1. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003; 4: CD001186.
2. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998; 102: 98-106.
3. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007; 119: 780-791.
4. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy. 2006; 61 (Suppl 82): 1-20.
5. Ameal A,Vega-Chicote JM, Fernandez S, Miranda A, Carmona MJ, Rondon MC, Reina E, Garcia-Gonzalez JJ. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy. 2005; 60: 1178-1183.
6. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000; 121: 229-234.
7. Annila IT, Karjalainen ES, Annila PA, Kuusisto PA. Bee and wasp sting reactions in current beekeepers. Ann Allergy Asthma Immunol. 1996; 77: 423-427.
8. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das Leitlinien-Manual von AWMF und ÄZQ. Z Ärztl Fortbild Qual Sich. 2001; 95: 1-84.
9. Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol. 2002; 109: 777-783.
10. ArzneimittelgesetzAMG. 14. Gesetz zur Änderung des Arzneimittelgesetzes. Bundesgesetzblatt. 2005; Teil I, Nr. 54.
11. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Stellungnahme der AkdÄ zur allergenspezifischen Immuntherapie. Dtsch Ärztebl. 2007; 104: A3355-3357.
12. Balda BR,Wolf H, Baumgarten C, Klimek L, Rasp G, Kunkel G, Müller S, Mann W, Hauswald B, HepptW, Przybilla B, Amon U, Bischoff R, Becher G, Hummel S, Frosch PJ, Rustemeyer T, Jäger L, Brehler R, Luger T. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy. 1998; 53: 740-748.
13. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2- to Th1-shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 1997; 27: 1131-1139.
14. Bergmann K-C. Spezifische Immuntherapie bei allergischem Asthma bronchiale. Pneumologie. 2003; 57: 84-90.
15. Bilo BM, Ruëff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. Allergy. 2005; 60: 1339-1349.
16. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy. 1993; 23: 226-230.
17. Blainey AD, Philips MJ, Ollier RJ, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. Allergy. 1984; 39: 521-528.
18. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy. 2006; 61: 843-848.
19. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy. 2002; 57: 297-305.
20. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immuno-therapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol. 2007; 120: 707-713.
21. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Müller U. Prevention and treatment of Hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005; 60: 1459-1470.
22. Bousquet J. Specific immunotherapy in asthma. Allergy. 1999; 54 (Suppl 56): 37-38.
23. Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy. 1986; 56: 456-459.
24. Bousquet J, Lockey RF, Malling H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy. 1998; 53: (Suppl 44): 1-42.
25. Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf. 1994; 10: 5-17.
26. Bousquet J, Michel FB, Malling HJ. Is allergen immunotherapy effective in asthma? Ameta-analysis of randomized clinical trials.AmJ Respir Crit Care Med. 1995; 152: 1737-1738.
27. Bousquet J, Müller UR, Dreborg S. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy. 1987; 42: 401-413.
28. Brehler R,Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol. 2000; 105: 1231-1235.
29. Brehler R, Wolf H, Luger T. Development of a three-day-protocol for the desensitization with insect venom. J Allergy Clin Immunol. 1999; 103: S181.
30. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1997; 100: 458-463.
31. Bucur J, Dreborg S, Einarsson R. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy. 1989; 62: 355-361.
32. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B,Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009; 123: 167-173.
33. Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, BraunW. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.Allergy. 2004; 59: 498-504.
34. Buhl R, Berdel D, Criée CP, Gillissen A, Kardos P, Kroegel C, Leupold W, Lindemann H, Magnussen H, Nowak D, Pfeiffer-Kascha D, Rabe K, Rolke M, Schultze-Werninghaus G, Sitter H, Ukena D, Vogelmeier C, Welte T, Wettengel R, Worth H. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie. 2006; 60: 139-183.
35. Bundesärztekammer. Eckpunkte der Bundesärztekammer für die Reanimation 2006. Dtsch Ärztebl. 2006; 103: A961-962.
36. Businco L, Zannino L, Cantani A, Corrias A, Fiocchi A, La Rosa M. Systemic reactions to specific immunotherapy in children with respiratory allergy: a prospective study. Pediatr Allergy Immunol. 1995; 6: 44-47.
37. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006; 118: 1292-1298.
38. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007; 1: CD001936.
39. Cockcroft DW, Cuff MT, Tarlo SM, Dolovich J, Hargreave FE. Allergen injection therapy with glutaraldehyde-modified ragweed pollen-tyrosine adsorbate. A double-blind trial. J Allergy Clin Immunol. 1977; 60: 56-62.
40. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005; 60: 801-807.
41. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma-and interleukin-10-production. Clin Exp Allergy. 2006; 36: 261-272.
42. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006; 117: 1021-1035.
43. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Riis B, Gronager PM, Durham SR. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008; 121: 512-518.
44. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, André C, de Beaumont O, Melac M. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 120: 1338-1345.
45. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001; 56: 498-505.
46. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S.Adouble-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986; 41: 131-140.
47. Durham SR,Walker SM, Varga EM, Jacobson MR, OBrien F, NobleW, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341: 468-475.
48. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006; 117: 802-809.
49. Elsner J, Sack A, Petering H, Schäfer T, Korner M, Kapp A. Ultrarush SIT in venom allergy. Allergy. 2000; 55: 582-583.
50. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006; 61: 198-201.
51. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy. 2002; 57: 306-312.
52. European Resuscitation Council. European Resuscitation Council Guidelines for Resuscitation 2005. Resuscitation. 2005; 67 (Suppl): S1-189.
53. European Resuscitation Council. Leitlinien des European Resuscitation Council 2005 zur Reanimation (Übersetzung). Notfall Rettungsmed. 2006; 9: 4-170.
54. Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest. 1976; 57: 1378-1385.
55. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy. 1988; 18: 501-508.
56. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol. 2003; 132: 13-24.
57. 4 inhibitory antibody activity. J Allergy Clin Immunol. 2008; 121: 1120-1125.
58. + T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003; 111: 1255-1261.
59. Garcia-Patos V, Pujol RM, Alomar A, Cistero A, Curell R, Fernandez-Figueras MT, de Moragas JM. Persistent subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Arch Dermatol. 1995; 131: 1421-1424.
60. Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2006; 118: 1026-1032.
61. Gillissen A, Bergmann K-C, Kleine-Tebbe J, Schultze-Werninghaus G, Virchow JC, Wahn U, Graf von der Schulenburg JM. Die spezifische Immuntherapie bei allergischem Asthma. Dtsch Med Wochenschr. 2003; 128: 204-209.
62. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulinG antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982; 70: 261-271.
63. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (updated 2005). GINA. 2005 (www.ginasthma.org).
64. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (updated 2008). GINA. 2009 (www.ginasthma.org).
65. Golden DB. Discontinuing venom immunotherapy. Curr Opin Allergy Clin Immunol. 2001; 1: 353-356.
66. Golden DB. Insect allergy in children. Curr Opin Allergy Clin Immunol. 2006; 6: 289-293.
67. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004; 351: 668-674.
68. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1981; 67: 370-374.
69. Golden DB, Valentine MD. Insect sting allergy. Ann Allergy. 1984; 53: 444-449.
70. Götzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy. 2008; 63: 646-659.
71. Hauser U,Wagenmann M, Rudack C, Cromwell O, Ganzer U. Specific immunotherapy suppresses IL-1b and IL-8 levels in nasal secretions: a possible explanation for the inhibition of inflammatory cell migration. Otorhinolaryngol Nova. 1997; 7: 31-39.
72. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, Sundin B, Løwenstein H. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol. 1991; 87: 955-964.
73. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C, Løwenstein H. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995; 96: 879-885.
74. Horst M, Hejjaoui A, Horst V, Michel F-B, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol.1990; 85: 460-472.
75. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, Frediani T. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. 2003; 14: 216-221.
76. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007; 62: 943-948.
77. Jappe U, Raulf-Heimsoth M, Hoffmann M, Burow G, Hübsch- Müller C, Enk A. In vitro Hymenoptera venom allergy diagnosis: improved by screening for cross-reactive carbohydrate determinants and reciprocal inhibition. Allergy. 2006; 61: 1220-1229.
78. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGFbeta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and spe-cific immunotherapy. Eur J Immunol. 2003; 33: 1205-1214.
79. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol. 1995; 154: 4187-4194.
80. Jutel M, Skrbic D, Pichler WJ, Müller UR. Ultra rush bee venom immunotherapy does not reduce cutaneous weal responses to bee venom and codeine phosphate. Clin Exp Allergy. 1995; 25: 1205-1210.
81. Kaul S, Jappe U, Vieths S, May S. Überwachung von Allergenextrakten zur spezifischen Immuntherapie: Rechtliche Grundlagen und Verfahren. Allergo J. 2008; 17: 385-393.
82. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol. 2004; 92: 225-227.
83. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004; 59: 45-53.
84. Kleine-Tebbe J. A bright future for sublingual immunotherapy - contra. Frankfurt am Main: Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe; 2006, 242-250, discussion 250-252.
85. Kleine-Tebbe J, Bachert C, Bergmann K-C, Bieber T, Brehler R, Friedrichs F, Fuchs T, Klimek L, Kopp MV, Lepp U, Przybilla B, Rebien W, Saloga J, Simon J,Wedi B,Werfel T,Worm M, Virchow JC. Aktueller Stellenwert der sublingualen Immuntherapie bei allergischen Krankheiten. Allergo J. 2007; 16: 492-500.
86. Kleine-Tebbe J, Bergmann K-C, Friedrichs F, Fuchs T, Jung K, Klimek L, Kühr J, LässigW, Lepp U, Niggemann B, Rakoski J, RebienW, Renz H, Saloga J, Simon J, Sitter H, Virchow J-C, Worm M. Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J. 2006; 15: 56-74 und Pädiatr Allergol. 2006; 1: 12-25.
87. Kleine-Tebbe J, Fuchs T, Klimek L, Kühr J, Lepp U, Niggemann B, Rakoski J, Renz H, Saloga J, Simon J. Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Positionspapier der DGAI, inhaltlich abgestimmt mit dem ÄDA. Allergo J. 2000; 9: 317-324.
88. Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz A, Schnitker J, Mann W. The effect of shortterm immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol. 1999; 103: 47-53.
89. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009; 39: 271-279.
90. Kopp MV, Niggemann B, Forster J. House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy. 2009; 64: 187-188, author reply 190.
91. Kühr J, Brauburger J, Zielen S, Schauer U, Kamin W, von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Grave M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109: 274-280.
92. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006; 6: 761-771.
93. Larenas-Linnemann DE, Cox LS. Sublingual immunotherapy for asthma: need for high quality meta-analyses to prove the concept. Allergy. 2007; 62: 704-705.
94. Li JT, Lockey RF, Bernstein I, Portnoy JM, Nicklas RA. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2003; 90: 1-40.
95. Löwer J, BeckerW-M, Vieths S. Regulatory control and standardization of allergenic extracts. 10th International Paul-Ehrlich-Seminar, October 2002, Lübeck, Germany. Arbeiten aus dem Paul-Ehrlich-Institut, Band 94. Frankfurt/Main: Druck- und Verlagshaus Sperlich; 2003.
96. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2001; 44: 709-718.
97. Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet. 2001; 357: 361-362.
98. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 2000; 23: 323-332.
99. Malling HJ. Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol. 2002; 2: 523-531.
100. Malling HJ. Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. Curr Opin Allergy Clin Immunol. 2004; 4: 539-542.
101. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy. 1986; 41: 507-519.
102. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol. 1998; 101: 506-513.
103. Mari A, Ballmer-Weber BK, Vieths S. The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol. 2005; 5: 267-273.
104. May S, Haustein D. Die individuelle Rezeptur in der spezifischen Immuntherapie. Notwendigkeit und Fehlerquellen. Bundesgesundheitsbl Gesund-heitsforsch Gesundheitsschutz. 2001; 44: 719-723.
105. McHugh SM, Ewan PW. Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy. Clin Exp Allergy. 1989; 19: 327-334.
106. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol. 1990; 86: 521-531.
107. Metzger WJ, Dorminey HC, Richerson HB,Weiler JM, Donnelly A, Moran D. Clinical and immunologic evaluation of glutaraldehyde-modified tyrosine-adsorbed short ragweed extract: a doubleblind, placebo-controlled trial. J Allergy Clin Immunol. 1981; 68: 442-448.
108. Möhrenschlager M, Kapp A, Kleine-Tebbe J, Bachert C, Ring J, Wüstenberg E. Lyophylisierte Graspollentablette zur sublingualen Immuntherapie bei Graspollenallergie: aktuellerWissensstand und Ergebnisse des Entwicklungsprogramms eines neuen Präparats. Allergologie. 2008; 31: 23-35.
109. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergenspecific sublingual immunotherapy. Allergy. 2006; 61: 151-165.
110. Möller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002; 109: 251-256.
111. Mosbech H, Malling HJ, Biering I, Böwadt H, Søborg M, Weeke B, Løwenstein H. Immunotherapy with yellow jacket venom. Acomparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy. 1986; 41: 95-103.
112. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003; 33: 1198-1208.
113. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998; 101: 747-754.
114. Müller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol. 1991; 87: 702-709.
115. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992; 89: 529-535.
116. Müller UR. Recent developments and future strategies for immunotherapy of insect venom allergy. Curr Opin Allergy Clin Immunol. 2003; 3: 299-303.
117. Müller UR, Mosbech H. Immunotherapy with Hymenoptera venoms. Position paper. Allergy. 1993; 48 (Suppl): 37-46.
118. Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - a placebo controlled study. Ann Allergy Asthma Immunol. 1999; 82: 485-490.
119. Nanda A, OConnor M, Anand M, Dreskin SC, Zhang L, Hines B, Lane D, Wheat W, Routes JM, Sawyer R, Rosenwasser LJ, Nelson HS. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol. 2004; 114: 1339-1344.
120. van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Wurtzen PA. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy. 2004; 34: 420-428.
121. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol. 1999; 163: 2944-2952.
122. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko A, Koller D, Norberg LA, Urbanek R, Valovirta E, Wahn U, Möller C. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006; 61: 855-859.
123. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004; 172: 3252-3259.
124. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007; 7: 542-546.
125. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, CaloriG, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004; 114: 851-857.
126. Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L, Pfaar O, Merk H. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009; 64: 179-186.
127. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001; 31: 1392-1397.
128. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy. 2003; 33: 1641-1647.
129. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol. 2007; 119: 881-891.
130. Pastorello E, Pravettoni V, Mambretti M, Franck E,Wahl R, Zanussi C. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy. 1992; 47: 281-290.
131. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N, Spitzauer S, Montagut A, Galvain S, Melac M, André C, Poulsen LK, Malling HJ. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008; 122: 951-960.
132. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, Canonica GW. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006; 97: 141-148.
133. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Canonica GW. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008; 133: 599-609.
134. Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008; 100: 256-263.
135. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house dust mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of non-specific bronchial hyperreactivity. Allergy. 2001; 56: 301-306.
136. Pichler CE, Marquardsen A, Sparholt S, Løwenstein H, Bircher A, Bischof M, Pichler WJ. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy. 1997; 52: 274-283.
137. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol. 1999; 103: 326-332.
138. Przybilla B, Ruëff F, Fuchs T, Pfeiffer C, Rakoski J, Stolz W, Vieluf D. Insektengiftallergie - Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J. 2004; 13: 186-190.
139. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy. 2005; 60: 678-684.
140. Purello-DAmbrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, Ricciardi L. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. Aretrospective study. Clin Exp Allergy. 2001; 31: 1295-1302.
141. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996; 26: 1253-1261.
142. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol.1988; 82: 470-480.
143. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, Villalba M, Durham SR, Becker WM, Aalbers M, André C, Barber D, Cistero Bahima A, Custovic A, Didierlaurent A, Dolman C, Dorpema JW, Di Felice G, Eberhardt F, Fernandez Caldas E. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy. 2008; 63: 310-326.
144. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy. 2000; 55: 484-488.
145. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003; 33: 206-210.
146. Ring J, Brockow K, Duda D, Eschenhagen T, Fuchs T, Huttegger I, Kapp A, Klimek L, Müller U, Niggemann B, Pfaar O, Przybilla B, Rebien W, Rietschel E, Ruëff F, Schnadt S, Tryba M,Worm M, Sitter H, Schultze-Werninghaus G. Akuttherapie anaphylaktischer Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA) und der Deutschen Akademie für Allergologie und Umweltmedizin (DAAU). Allergo J. 2007; 16: 420-434.
147. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977; 1: 466-469.
148. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997; 99: 450-453.
149. Röder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008; 19: 197-207.
150. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, Kuehr J, Zielen S, Schauer U, KaminW, von Berg A, Hammermann J, Weinkauf B, Weidinger G, Stenglein S, Wahn U. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59: 973-979.
151. Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy. 2004; 59: 1285-1293.
152. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol. 2006; 16: 79-85.
153. Ruëff F, Przybilla B. Venom immunotherapy: adverse reactions and treatment failure. Curr Opin Allergy Clin Immunol. 2004; 4: 307-311.
154. Ruëff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy. 1996; 51: 216-225.
155. Schäfer T. Allergieprävention - evidenzbasierte und konsentierte Leitlinie. Allergo J. 2009; 18: 332-341.
156. Schäfer T, Przybilla B. IgE antibodies to Hymenoptera venoms in the serum are common in the general population and are related to indications of atopy. Allergy. 1996; 51: 372-377.
157. Schultze-Werninghaus G. Aufklärung bei allergischen Erkrankungen. Leserforum. Allergo J. 1993; 2: 10-11.
158. + T cells from allergic individuals. J Exp Med. 1993; 178: 2123-2130.
159. Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol. 2002; 110: 928-933.
160. Sundin B, Lilja G, Graff-Lonnevig V, Hedlin G, Heilborn H, Norrlind K, Pegelow KO, Løwenstein H. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol. 1986; 77: 478-487.
161. Tari MG, Mancino M, Ghezzi E, Frank E, Cromwell O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study. Allergy. 1997; 52: 65-74.
162. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, Spitzauer S, Swoboda I, Vrtala S, Westritschnig K, Kraft D. Immunotherapy of allergic disease. Adv Immunol. 2004; 82: 105-153.
163. Verordnung über die Ausdehnung derVorschriften über die Zulassung der Arzneimittel auf Therapieallergene, die für einzelne Personen aufgrund einer Rezeptur hergestellt werden, sowie über Verfahrensregelungen der staatlichen Chargenprüfung (Therapieallergene- Verordnung). Bundesgesetzblatt. 2008; Teil I, Nr. 51: 2177-2178.
164. Vogelbruch M, Nuss B, Korner M, Kapp A, Kiehl P, Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy. 2000; 55: 883-887.
165. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, Beaumont O de, Le Gall M. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009; 123: 160-166.
166. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, Chen P, Sheng J, Wu A, Zhong N. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006; 61: 191-197.
167. Werfel T, Breuer K, Ruëff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R,Wolf H, Schnitker J, Kapp A. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006; 61: 202-205.
168. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003; 2: CD002893.
169. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Allerg Immunol (Paris). 2006; 38: 355-360.
170. Wüthrich B, Gumowski PL, Fah J, Hurlimann A, Deluze C, André C, Fadel R, Carat F. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide. J Investig Allergol Clin Immunol. 2001; 11: 149-156.
171. Yunginger JW, Paull BR, Jones RT, Santrach RJ. Rush venom immunotherapy program for honeybee sting sensitivity. J Allergy Clin Immunol. 1979; 63: 340-347.
172. Zenner HP, Baumgarten C, Rasp G, Fuchs T, KunkelG, Hauswald B, Ring J, Effendy I, Behrendt W, Frosch PJ, Przybilla B, Brunner FX, Merk HF, Kapp A, Schnitker J, Wolf H. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol. 1997; 100: 23-29.